Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
- Conditions
- Alzheimer's Disease DementiaMild Cognitive Impairment Due to Alzheimer's Disease
- Interventions
- Drug: BIIB080-matching placebo
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 416
- Registration Number
- NCT05399888
- Locations
- 🇺🇸
Xenoscience Inc., Phoenix, Arizona, United States
🇺🇸HonorHealth Neurology, Scottsdale, Arizona, United States
🇺🇸Banner Sun Health Research Institute, Sun City, Arizona, United States
Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy
- Conditions
- Spinal Muscular Atrophy (SMA)
- Interventions
- Device: Virtual realityProcedure: Standard of Care
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 63
- Registration Number
- NCT05354414
- Locations
- 🇫🇷
Chu d' Angers, Angers, France
🇫🇷CHRU de Brest, Brest, France
🇫🇷Chu de Clermont Ferrand, Clermont Ferrand, France
An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Drug: Litifilimab-matching placebo
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Biogen
- Target Recruit Count
- 864
- Registration Number
- NCT05352919
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona, United States
🇺🇸Wallace Rheumatic Study Center, Beverly Hills, California, United States
🇺🇸Care Access Research - Huntington Beach, Huntington Beach, California, United States
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
- Conditions
- Parkinson Disease
- Interventions
- Drug: BIIB122-Matching Placebo
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 650
- Registration Number
- NCT05348785
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Banner Sun Health Research Institute, Sun City, Arizona, United States
🇺🇸University of Southern California, Los Angeles, California, United States
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1512
- Registration Number
- NCT05310071
- Locations
- 🇺🇸
Gilbert Neurology Partners, PLLC, Gilbert, Arizona, United States
🇺🇸Xenoscience Inc., Phoenix, Arizona, United States
🇺🇸Banner Alzheimer's Institute, Tucson, Arizona, United States
A Study for Tysabri Participant Preference
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 318
- Registration Number
- NCT05304520
- Locations
- 🇩🇪
Neurozentrum am Königsplatz Augsburg; Dres. Müller und Schmid, Augsburg, Germany
🇩🇪Praxis Dr. Schöll, Bad Homburg, Germany
🇩🇪Caritas Krankenhaus Bad Mergentheim, Bad Mergentheim, Germany
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 21
- Registration Number
- NCT05265728
- Locations
- 🇯🇵
Juntendo University Hospital, Bunkyo-ku, Japan
🇯🇵Chiba University Hospital, Chiba-shi, Japan
🇯🇵St.Marianna University Hospital, Kawasaki-shi, Japan
TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 675
- Registration Number
- NCT05236777
- Locations
- 🇨🇿
Fakultní nemocnice Brno, Brno, Czechia
🇨🇿Fakultní nemocnice u sv. Anny v Brně, Brno, Czechia
🇨🇿Fakultní nemocnice Hradec Králové, Hradec Králové, Czechia
A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 84
- Registration Number
- NCT05229562
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- Biological: Aducanumab
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 123
- Registration Number
- NCT05216887
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸QPS-MRA, Miami, Florida, United States
🇺🇸QPS Missouri, Springfield, Missouri, United States